Latest Diamyd Medical News & Updates

See the latest news and media coverage for Diamyd Medical. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Diamyd Medical

Clinical-stage diabetes therapy developer

diamyd.com
Headquarters
Stockholm, Sweden
Company type
Public company
Number of employees
10–70

Latest news about Diamyd Medical

Company announcements

  • Diamyd Medical

    Diamyd Medical announces leadership changes

    Anders Essen-Möller is appointed CEO and Erik Nerpin as Chairman of the Board. Ulf Hannelius leaves the CEO role.

  • Diamyd Medical

    Diamyd Medical announces management changes

    CEO Ulf Hannelius steps down after failed study. Anders Essen-Möller becomes executive chairman. Strategic review ongoing.

  • Diamyd Medical

    Diamyd Medical terminates the DIAGNODE-3 study

    After interim analysis, lack of effect is confirmed. The company initiates strategic review of the organization and alternatives.

  • Diamyd Medical

    Diamyd Medical's extraordinary general meeting approves issuance of warrants

    The meeting on April 8, 2026 decided on a maximum of 24,875,066 options to Günther & Wikberg Holding AB as settlement institution.

Unlock all announcements with a

Media coverage

  • Dagens industri

    Diamyd's founder steps in as CEO

    The day after the announcement that Diamyd Medical's CEO Ulf Hannelius is leaving his role due to the company's study failure and share price collapse, the company announces that the founder...

  • FinanzNachrichten

    Diamyd Medical AB (publ): Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming futility; initiates strategic review

    Diamyd Medical today announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes. Following the previously...

  • Dagens industri

    Diamyd initiates strategic review after study failure

    Diamyd Medical fell heavily after a study failure at the end of March. The company now announces that the study is discontinued, and initiates a strategic review...

  • BioCentury

    BioCentury - Dyamed’s subgroup success doesn’t translate to Phase III in Type I diabetes, Kodiak data and more

    Diamyd Medical AB (SSE:DMYD B) lost 89% of its value Monday after a readout on Friday for the company’s retogatein vaccine, designed to produce immune...

Unlock all articles with a

Never miss news about Diamyd Medical

Track Diamyd Medical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Diamyd Medical competitors & trending companies

Browse news for competitors to Diamyd Medical and other trending companies.